Interesting article in today’s Wall Street Journal on the use of genetic tools to resuscitate failed compounds.
Here how the story begins:
“As pharmaceutical makers find it increasingly difficult to bring new drugs to market, they are turning to genetic tools to seek uses for medicines that failed to make it out of the development pipeline.
The discovery of new links between genes and diseases can help not only to design new treatments, but to salvage drugs that are shelved when they come up short in clinical trials.â€
And here’s the rest of the story:
http://online.wsj.com/article/SB120631682077958247.html?mod=dist_smartbrief
The better understanding of genetic tools (via a robust collaboration of industry, academia, and government) will both expedite failure (which lowers the cost of R&D) and provide a broader spectrum for success (which rewards it).
Sound familiar? Correct – the Critical Path.
Here how the story begins:
“As pharmaceutical makers find it increasingly difficult to bring new drugs to market, they are turning to genetic tools to seek uses for medicines that failed to make it out of the development pipeline.
The discovery of new links between genes and diseases can help not only to design new treatments, but to salvage drugs that are shelved when they come up short in clinical trials.â€
And here’s the rest of the story:
http://online.wsj.com/article/SB120631682077958247.html?mod=dist_smartbrief
The better understanding of genetic tools (via a robust collaboration of industry, academia, and government) will both expedite failure (which lowers the cost of R&D) and provide a broader spectrum for success (which rewards it).
Sound familiar? Correct – the Critical Path.
